Company Description
AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases.
It is developing epetraborole, which is in a pivotal Phase 2/3 clinical trial as a once-daily oral treatment for patients with non-tuberculous mycobacterial lung disease.
The company also develops AN2-502998 (AN15368), an investigational, boron-based small molecule in development for the treatment of chronic Chagas disease that is in preclinical trials.
It has a license agreement with Anacor Pharmaceuticals, Inc. to use, develop, manufacture, commercialize, or otherwise exploit certain compounds and products, including epetraborole, for the treatment, diagnosis, or prevention of all human diseases; and Brii Biosciences Limited to research, develop, manufacture, and commercialize certain compounds and products, including epetraborole, in China, Hong Kong, Taiwan, and Macau for the diagnosis, treatment, and prevention of human diseases.
The company was incorporated in 2017 and is headquartered in Menlo Park, California.
| Country | United States |
| Founded | 2017 |
| IPO Date | Mar 25, 2022 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 41 |
| CEO | Eric E. Easom |
Contact Details
Address: 1800 El Camino Real, Suite D Menlo Park, California 94027 United States | |
| Phone | (650) 331-9090 |
| Website | an2therapeutics.com |
Stock Details
| Ticker Symbol | ANTX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $15.00 |
| CIK Code | 0001880438 |
| CUSIP Number | 037326105 |
| ISIN Number | US0373261058 |
| Employer ID | 82-0606654 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Joseph S. Zakrzewski | Co-founder and Chairman of the Board |
| Eric E. Easom | Co-founder, Chief Executive Officer, President and Director |
| Joshua Eizen J.D. | Chief Legal Officer and Secretary |
| Dr. Paul Eckburg M.D. | Chief Medical Officer |
| Dr. George Harrison Talbot FACP, M.D. | Co-Founder and Senior Clinical Advisor |
| Dr. Michael R. K. Alley Ph.D. | Co-Founder and Head of Biology |
| Lucy O. Day CPA | Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer |
| Dr. Sanjay Chanda Ph.D. | Chief Development Officer |
| Kevin Krause B.S., M.B.A. | Chief Strategy Officer |
| Jennifer Huber | Senior Vice President of Regulatory Affairs and Quality |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 26, 2024 | ARS | Filing |
| Apr 26, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 26, 2024 | DEF 14A | Other definitive proxy statements |
| Apr 10, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Apr 5, 2024 | PRE 14A | Other preliminary proxy statements |
| Mar 29, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 29, 2024 | 10-K | Annual Report |
| Mar 28, 2024 | 8-K | Current Report |
| Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |